Zeiss Receives FDA Clearance for Epithelial Thickness Mapping for Cirrus HD-OCT


DUBLIN, Calif.—Zeiss Medical Technology Segment has received 510(k) clearance from the FDA for the Cirrus HD-OCT platform, expanding the capabilities of its Anterior Segment Premier Module to include Epithelial Thickness Mapping (ETM). The technology helps eye doctors better identify eligible patients for refractive surgery as well as monitor the cornea’s post-surgical healing response, according to Zeiss. ETM with Cirrus provides a detailed nine-millimeter map of epithelial thickness that enables more thorough assessment of patients before refractive surgery, allows monitoring of the cornea’s response to treatment, and aids in managing patients with ocular surface disorders such as dry eye and progressive corneal diseases such as keratoconus.

With ETM, patients can expect a quick, comfortable non-contact exam that takes less than one-second. Zeiss will unveil the new ETM feature in the latest Cirrus software release, along with other products at Vision Expo East in New York, March 21 to 24.